relmada - Search News

Relmada acquires neurosteroid from Asarina

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for Tourette's syndrome (TS) and other compulsive disorders.

Business Insider · 2d

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed

Investing.com on MSN · 2d

Relmada acquires new Tourette syndrome treatment asset

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid,

The Pharma Letter · 1d

Relmada in-licenses Tourette syndrome drug from Asarina

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.

Business Insider · 2d

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from

FierceBiotech1d

After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Investing1d

Relmada Therapeutics Inc (RLMD)

This page features the latest news about the Relmada Therapeutics stock. RLMD stock touches 52-week low at $0.35 amid market challenges In a turbulent market environment, Relmada Therapeutics Inc ...

10d

Relmada Therapeutics (NASDAQ:RLMD) Receives Notification from Nasdaq Regarding Minimum Bid Price Compliance

Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...

Benzinga.com2mon

Relmada Therapeutics (NASDAQ:RLMD) Stock Quotes, Forecast and News Summary

Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.

5don MSN

RLMD stock touches 52-week low at $0.34 amid sharp annual decline

In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results